Ajay Piramal’s missed decade
The speed at which Piramal Enterprises grew its real estate loan book would put a SoftBank-funded startup to shame. It’s time for a reset.

Why read this story?
Editor's note: Ajay Piramal is no ordinary businessman. Starting in the late 1980s, with a mere Rs 6 crore in capital, he built a significant pharmaceuticals business which he sold for over Rs 17,000 crore, a little over two decades later. In dollar terms, that’s going from about $4-5 million (at 1988 exchange rates) to $3.7 billion (at 2010 rates). In doing so, Piramal created a precedent that most Indian businessmen can only dream of. Rs 1,000 invested in his company in 1988 would have been worth Rs 29 lakh when he sold the pharma business to US-based Abbott Laboratories in 2010, a compound annual growth rate of 43%. An investment in the 30-stock Sensex would have paled in comparison with a 17% annualized return. In those early heady days, Shekhar Gupta, the then editor of The Indian Express, had called Piramal India’s Warren Buffett on his talk show. The legendary American investor who ran Berkshire Hathaway had returned 15% in the preceding two decades. That’s how the legend of Ajay Piramal was born. Cemented only further in the context that Piramal …
More in Business
You may also like
Reliance’s growth engines may be losing steam
Telecom and retail, which account for half the conglomerate’s revenue and most of its valuation, aren’t accelerating fast enough to justify their price tags.
Bajaj Housing Finance could use a dose of risk
The NBFC’s stock has fizzled a fair bit since its dream debut despite doing all the right things. Competition, circumstances and conservatism are ailing it.
Conglomerates, duopolies and domination hamper India
The domination of a few business groups—conglomerates—is a defining feature of the country’s economy. This has been enabled by policy, leading to stifled innovation and hindered progress. All of this, in turn, exacerbates inequalities.






